TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)
This is a discussion on TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal). It links ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-01-2010, 12:51 PM
|
|||
|
|||
TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)
The summary for the published technology appraisal on Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal). It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA148: Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed | industry_news | Updates from the Technology Assessment Authorities | 0 | 09-22-2009 08:06 PM |
| Gefitinib as Effective as Docetaxel in Non-Small-Cell Lung Cancer | industry_news | Other Clinical Pharmacy News | 0 | 11-25-2008 06:13 PM |
| First-Line Chemo for Small-Cell Lung Cancer is Not Superior to Second-Line | industry_news | Other Clinical Pharmacy News | 0 | 10-08-2008 09:21 AM |
© 2008 DrugManagementForum™ powered by |
 |